Japan has just over half the amount of registered dermatologists of the US.. And at the end of 2024 we’re averaging 45 new prescriptions each per year.
Currently the US is averaging 0.2 new prescriptions per registered dermatologist..
It gives you another angle on where and how exponential potential growth may lie, and why BOT management are trying to fast track early adoption of Sofdra..
Its quite exciting where BOT may be in sales in 12 months, and even more exciting projecting another 12 months in forward looking revenues from refills.
I have no idea if there is another company on the ASX with this potential for explosive growth. But, I’ll be not even considering selling any shares until any of the key fundamentals are no longer in play- payer coverage issue, refill rate under 8, or they are running a net loss after 18 months of explosive revenue growth..
BOT Price at posting:
42.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)